ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 272.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 767,265 shares of the biotechnology company's stock after acquiring an additional 561,310 shares during the period. JPMorgan Chase & Co. owned 0.32% of ADMA Biologics worth $13,159,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. National Bank of Canada FI acquired a new stake in ADMA Biologics in the third quarter valued at about $35,000. GAMMA Investing LLC lifted its holdings in shares of ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock valued at $32,000 after buying an additional 967 shares during the period. Mark Sheptoff Financial Planning LLC purchased a new stake in shares of ADMA Biologics in the fourth quarter valued at approximately $35,000. Vision Financial Markets LLC acquired a new position in ADMA Biologics during the fourth quarter worth $51,000. Finally, AlphaQuest LLC purchased a new position in ADMA Biologics in the fourth quarter worth $84,000. Hedge funds and other institutional investors own 75.68% of the company's stock.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th.

Remove Ads

ADMA Biologics Stock Up 5.9 %

Shares of ADMA Biologics stock traded up $1.24 during trading hours on Tuesday, hitting $22.15. 7,152,085 shares of the company's stock traded hands, compared to its average volume of 3,589,959. The stock has a 50 day simple moving average of $17.86 and a 200-day simple moving average of $18.16. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a twelve month low of $5.91 and a twelve month high of $23.64. The company has a market cap of $5.24 billion, a PE ratio of 79.11 and a beta of 0.53.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.